Hiroyuki Ida
Research Subjects
Hiroyuki Ida has a total of 76 co-authors. Here are the top co-authors by number of shared publications:
- Mio Sakuma
Department of Data Science, Hyogo Medical University, Nishinomiya 663-8501, Japan
3 shared publications - Takeshi Morimoto
Department of Data Science, Hyogo Medical University, Nishinomiya 663-8501, Japan
3 shared publications - Daishi Hirano
Department of Pediatrics, The Jikei University School of Medicine, Tokyo, Japan
2 shared publications - Jiro Takeuchi
Department of Clinical and Translational Science, Nara Medical University, Nara 634-8521, Japan
2 shared publications - Kei Murayama
Diagnostics and Therapeutics of Intractable Diseases, Intractable Disease Research Center, Graduate School of Medicine, Juntendo University, Bunkyo-ku, Tokyo 113-8421, Japan
2 shared publications - Yuki Yuza
Department of Hematology/Oncology, Tokyo Metropolitan Children’s Medical Center, 2-8-29, Musashidai, Fuchu, Tokyo 183-8561, Japan
2 shared publications
Latest Publications
- 8 October 2026
- Published by Wolters Kluwer Health in Journal of Patient Safety
Adverse Events due to Surgical Procedures Among Pediatric Inpatients: The Japan Adverse Event Study
Objectives: Adverse events (AEs) and medical errors (MEs) related to surgery in pediatric inpatients are critical concerns. However, comprehensive epidemiological data across pediatric surgeries remain limited. We aimed to examine the detailed epidemiology of AEs and MEs related to surgery. Methods: We analyzed data from the Japan Adverse Events Study, a retrospective cohort study conducted at 2 tertiary care teaching hospitals in Japan. We included patients who underwent surgery, classified as major or minor. Major surgeries involved access to major body cavities or deep structures with anatomic modification, whereas minor surgeries involved only superficial approaches. Results: Of 328 surgical patients [4261 patient-days], 87 had major and 241 had minor surgeries. The median age was 1 year (interquartile range: 0-8) in the major surgery group and 4 years (interquartile range: 1-7) in the minor surgery group ( P = 0.03). A total of 292 AEs were identified: 156 in the major and 136 in the minor surgery group (83 versus 57 per 1000 patient-days, P = 0.001). Life-threatening AEs occurred numerically more frequently in the major surgery group (5% versus 2%, P = 0.53). The incidence of MEs was similar (33 versus 37 per 1000 patient-days), but MEs were more likely to result in AEs in the major surgery group [22/61 (36%) versus 14/88 (16%), P = 0.005]. Conclusions: AEs occurred more frequently, and MEs were more likely to result in AEs in the major than in the minor surgery group. These findings suggest that perioperative patient safety strategies should be tailored according to surgical invasiveness.
- 8 October 2026
- Published by Wolters Kluwer Health in Journal of Patient Safety
Adverse Events due to Surgical Procedures Among Pediatric Inpatients: The Japan Adverse Event Study
Objectives: Adverse events (AEs) and medical errors (MEs) related to surgery in pediatric inpatients are critical concerns. However, comprehensive epidemiological data across pediatric surgeries remain limited. We aimed to examine the detailed epidemiology of AEs and MEs related to surgery. Methods: We analyzed data from the Japan Adverse Events Study, a retrospective cohort study conducted at 2 tertiary care teaching hospitals in Japan. We included patients who underwent surgery, classified as major or minor. Major surgeries involved access to major body cavities or deep structures with anatomic modification, whereas minor surgeries involved only superficial approaches. Results: Of 328 surgical patients [4261 patient-days], 87 had major and 241 had minor surgeries. The median age was 1 year (interquartile range: 0-8) in the major surgery group and 4 years (interquartile range: 1-7) in the minor surgery group ( P = 0.03). A total of 292 AEs were identified: 156 in the major and 136 in the minor surgery group (83 versus 57 per 1000 patient-days, P = 0.001). Life-threatening AEs occurred numerically more frequently in the major surgery group (5% versus 2%, P = 0.53). The incidence of MEs was similar (33 versus 37 per 1000 patient-days), but MEs were more likely to result in AEs in the major surgery group [22/61 (36%) versus 14/88 (16%), P = 0.005]. Conclusions: AEs occurred more frequently, and MEs were more likely to result in AEs in the major than in the minor surgery group. These findings suggest that perioperative patient safety strategies should be tailored according to surgical invasiveness.
- Open Access
- 1 January 2025
- Published by Japanese Society for Pediatric Nephrology in Japanese journal of pediatric nephrology
- Vol. 38, oa.24-027
Study on the utility of ultrasonography in the differential diagnosis of febrile urinary tract infection
【背景および目的】有熱性尿路感染症(febrile urinary tract infection: fUTI)における急性腎盂腎炎と急性巣状細菌性腎炎(acute focal bacterial nephritis: AFBN)の鑑別は治療方針の決定に重要である.現在,AFBNの診断のgold standardは造影CTでの限局した低吸収域の検出である.本研究では,AFBNの診断における超音波検査(ultrasonography: US)の有用性を,特に陽性的中率(positive predictive value: PPV)の観点から評価することを目的とした.【方法】2020年9月から2023年8月に初発のfUTIで入院した小児103名を対象に後方視的研究を実施した.【結果】USによるAFBNの診断基準を境界不明瞭な巣状の腫瘤と局所的な血流欠損とし,これに合致した10名中9名に造影CTを実施した結果,全例でUSと一致する部位に腫瘤状の不均一な造影不良域を認めた.AFBNに対するUSでのPPVは100%と高値を示した.【結論】USでAFBNが疑われる場合,必ずしも造影CTが必須ではない可能性が示唆された.
- 1 January 2025
- Published by Japanese Society for Pediatric Nephrology in Japanese journal of pediatric nephrology
- Vol. 38, oa.24-027
Open AccessStudy on the utility of ultrasonography in the differential diagnosis of febrile urinary tract infection
【背景および目的】有熱性尿路感染症(febrile urinary tract infection: fUTI)における急性腎盂腎炎と急性巣状細菌性腎炎(acute focal bacterial nephritis: AFBN)の鑑別は治療方針の決定に重要である.現在,AFBNの診断のgold standardは造影CTでの限局した低吸収域の検出である.本研究では,AFBNの診断における超音波検査(ultrasonography: US)の有用性を,特に陽性的中率(positive predictive value: PPV)の観点から評価することを目的とした.【方法】2020年9月から2023年8月に初発のfUTIで入院した小児103名を対象に後方視的研究を実施した.【結果】USによるAFBNの診断基準を境界不明瞭な巣状の腫瘤と局所的な血流欠損とし,これに合致した10名中9名に造影CTを実施した結果,全例でUSと一致する部位に腫瘤状の不均一な造影不良域を認めた.AFBNに対するUSでのPPVは100%と高値を示した.【結論】USでAFBNが疑われる場合,必ずしも造影CTが必須ではない可能性が示唆された.
- Open Access
- 6 November 2023
- Published by Wolters Kluwer Health in Journal of Patient Safety
- Vol. 20 (1) , 38-44
Adverse Events in Pediatric Inpatients: The Japan Adverse Event Study
Objectives: Adverse events (AEs) represent an important cause of morbidity and mortality for pediatric inpatients; however, reports on their epidemiology in pediatrics, especially outside Western countries, are scarce. We investigated the incidence and nature of AEs in pediatric inpatients in Japan. Methods: Trained pediatrician and pediatric nurses reviewed all medical documents of 1126 pediatric inpatients in 2 tertiary care teaching hospitals in Japan, and potential incidents were collected with patients’ characteristics. Age was categorized into 6 groups (neonates, infants, preschoolers, school-aged children, teenagers, and over-aged pediatric patients), and medical care when potential incidents occurred was classified into drug, operation, procedure/examinations, nursing, management, and judgment. Physician reviewers independently evaluated all collected incidents into AEs, potential AEs, medical errors, and exclusions and assessed their severity and preventability. Results: A total of 1126 patients with 12,624 patient-days were enrolled, and 953 AEs, with an incidence of 76 (95% confidence interval, 71–80) per 1000 patient-days, were identified. Preventable AEs accounted for 23% (218/953) of AEs. The incidence of AEs tended to decrease with increasing age. The proportion of AEs that were preventable was highest in neonates (40%), and this proportion decreased as children aged. Both judgment and management-related AEs were considered preventable AEs, and judgment-related AEs were more severe AEs than no-judgment–related AEs; 43% were life-threatening. Conclusions: Adverse events were common in Japanese pediatric inpatients, and their preventability and severity varied considerably by age category and medical care. Further investigation is needed to address which strategies might most improve pediatric patient safety.
- 6 November 2023
- Published by Wolters Kluwer Health in Journal of Patient Safety
- Vol. 20 (1) , 38-44
Open AccessAdverse Events in Pediatric Inpatients: The Japan Adverse Event Study
Objectives: Adverse events (AEs) represent an important cause of morbidity and mortality for pediatric inpatients; however, reports on their epidemiology in pediatrics, especially outside Western countries, are scarce. We investigated the incidence and nature of AEs in pediatric inpatients in Japan. Methods: Trained pediatrician and pediatric nurses reviewed all medical documents of 1126 pediatric inpatients in 2 tertiary care teaching hospitals in Japan, and potential incidents were collected with patients’ characteristics. Age was categorized into 6 groups (neonates, infants, preschoolers, school-aged children, teenagers, and over-aged pediatric patients), and medical care when potential incidents occurred was classified into drug, operation, procedure/examinations, nursing, management, and judgment. Physician reviewers independently evaluated all collected incidents into AEs, potential AEs, medical errors, and exclusions and assessed their severity and preventability. Results: A total of 1126 patients with 12,624 patient-days were enrolled, and 953 AEs, with an incidence of 76 (95% confidence interval, 71–80) per 1000 patient-days, were identified. Preventable AEs accounted for 23% (218/953) of AEs. The incidence of AEs tended to decrease with increasing age. The proportion of AEs that were preventable was highest in neonates (40%), and this proportion decreased as children aged. Both judgment and management-related AEs were considered preventable AEs, and judgment-related AEs were more severe AEs than no-judgment–related AEs; 43% were life-threatening. Conclusions: Adverse events were common in Japanese pediatric inpatients, and their preventability and severity varied considerably by age category and medical care. Further investigation is needed to address which strategies might most improve pediatric patient safety.
- Open Access
- 4 December 2021
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 16 (1) , 1-8
Long-term safety and effectiveness of velaglucerase alfa in Gaucher disease: 6-year interim analysis of a post-marketing surveillance in Japan
Background: Gaucher disease (GD) is caused by reduced lysosomal enzyme β-glucocerebrosidase activity. Heterogeneous genotypes and phenotypes have been observed within GD types and across ethnicities. Enzyme replacement therapy is generally recommended for patients with type 1 GD, the least severe form of GD. In Japan, velaglucerase alfa has a broad indication covering type 1, 2 or 3 GD. Methods: All patients with type 1, 2, or 3 GD administered velaglucerase alfa 60 U/kg every 2 weeks via intravenous infusion after its launch date in Japan in 2014, were enrolled in a non-interventional, observational post-marketing surveillance (PMS). Individual patient data were reported via case report forms (CRFs). Key safety endpoints investigated included the incidence of infusion-related reactions (IRRs), the safety of velaglucerase alfa in patients with types 2 and 3 GD, from patients under one year of age to elderly patients (≥ 65 years of age). Long-term efficacy was also assessed. Results: In total, 53 patients with GD were registered. CRFs were available for 41 (77.4%) patients at the 6-year interim analysis. Fourteen adverse drug reactions (ADRs) were reported in seven patients. All reported ADRs occurred in patients with type 2 GD. ADRs were reported by 63.6% (7/11) of patients with type 2 GD. Ten ADRs were reported in five patients aged < 4 years. No elderly patients experienced any ADR during the surveillance period. Five ADRs occurring in three (10.0%) patients were classified as IRRs, with one case of vomiting (moderate severity) resulting in treatment discontinuation. Ten serious adverse events were reported in five (16.7%) patients. Three fatal events were considered to be unrelated to treatment with velaglucerase alfa. Platelet counts increased after the administration of velaglucerase alfa and were generally maintained within the normal range over the administration period. Among eleven patients tested for neutralizing anti-velaglucerase alfa antibodies, two (18.2%) were assessed as positive results. Conclusion: PMS data from patients with types 1–3 GD in Japan indicate that long-term treatment with velaglucerase alfa was well-tolerated and associated with increased platelet counts, which is consistent with observations made in studies outside of Japan. Trial registration: NCT03625882 registered July 2014.
- 4 December 2021
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 16 (1) , 1-8
Open AccessLong-term safety and effectiveness of velaglucerase alfa in Gaucher disease: 6-year interim analysis of a post-marketing surveillance in Japan
Background: Gaucher disease (GD) is caused by reduced lysosomal enzyme β-glucocerebrosidase activity. Heterogeneous genotypes and phenotypes have been observed within GD types and across ethnicities. Enzyme replacement therapy is generally recommended for patients with type 1 GD, the least severe form of GD. In Japan, velaglucerase alfa has a broad indication covering type 1, 2 or 3 GD. Methods: All patients with type 1, 2, or 3 GD administered velaglucerase alfa 60 U/kg every 2 weeks via intravenous infusion after its launch date in Japan in 2014, were enrolled in a non-interventional, observational post-marketing surveillance (PMS). Individual patient data were reported via case report forms (CRFs). Key safety endpoints investigated included the incidence of infusion-related reactions (IRRs), the safety of velaglucerase alfa in patients with types 2 and 3 GD, from patients under one year of age to elderly patients (≥ 65 years of age). Long-term efficacy was also assessed. Results: In total, 53 patients with GD were registered. CRFs were available for 41 (77.4%) patients at the 6-year interim analysis. Fourteen adverse drug reactions (ADRs) were reported in seven patients. All reported ADRs occurred in patients with type 2 GD. ADRs were reported by 63.6% (7/11) of patients with type 2 GD. Ten ADRs were reported in five patients aged < 4 years. No elderly patients experienced any ADR during the surveillance period. Five ADRs occurring in three (10.0%) patients were classified as IRRs, with one case of vomiting (moderate severity) resulting in treatment discontinuation. Ten serious adverse events were reported in five (16.7%) patients. Three fatal events were considered to be unrelated to treatment with velaglucerase alfa. Platelet counts increased after the administration of velaglucerase alfa and were generally maintained within the normal range over the administration period. Among eleven patients tested for neutralizing anti-velaglucerase alfa antibodies, two (18.2%) were assessed as positive results. Conclusion: PMS data from patients with types 1–3 GD in Japan indicate that long-term treatment with velaglucerase alfa was well-tolerated and associated with increased platelet counts, which is consistent with observations made in studies outside of Japan. Trial registration: NCT03625882 registered July 2014.
- Open Access
- 11 October 2021
- Published by SAGE Publications in Journal of Patient Safety and Risk Management
- Vol. 26 (6) , 261-266
Differences in adverse drug events and medication errors among pediatric inpatients aged <3 and ≥3 years: The JADE study
Background: Adverse drug events (ADEs) are defined as any injuries due to medication use. We hypothesized that the incidences of ADEs and medication errors (MEs) could be associated with linguistic skills of pediatric patients. Methods: We analyzed data from the Japan Adverse Drug Events study on pediatric inpatients. This study included inpatients aged one months and older and less than seven years old. We compared the primary outcome of ADEs and MEs between patients aged under three years and three years and older as children typically do not acquire sufficient linguistic skills until around three years of age. Results: This study included 639 patients; 412 (64%) patients aged under three years and 227 (36%) patients aged three years and older. We identified 241 ADEs in 639 patients; 152 ADEs among patients aged under three years (37 ADEs per 100 patients) and 89 ADEs among those aged three years and older (39 ADEs per 100 patients). ADEs among patients aged under three years were less likely to be found (49 ADEs) during their hospital stay than those aged three years and older (20 ADEs) ( P = 0.02). Among 172 MEs identified in 639 patients, 25 MEs (15%) resulted in ADEs; 23 (92%) occurred to those aged under three years and two (8%) occurred to those aged three years and older ( P = 0.0008). Conclusion: ADEs were less likely to be found and MEs resulted in ADEs more frequently in patients under three years old, and these differences could be explained by differences in their linguistic skill levels.
- 11 October 2021
- Published by SAGE Publications in Journal of Patient Safety and Risk Management
- Vol. 26 (6) , 261-266
Open AccessDifferences in adverse drug events and medication errors among pediatric inpatients aged <3 and ≥3 years: The JADE study
Background: Adverse drug events (ADEs) are defined as any injuries due to medication use. We hypothesized that the incidences of ADEs and medication errors (MEs) could be associated with linguistic skills of pediatric patients. Methods: We analyzed data from the Japan Adverse Drug Events study on pediatric inpatients. This study included inpatients aged one months and older and less than seven years old. We compared the primary outcome of ADEs and MEs between patients aged under three years and three years and older as children typically do not acquire sufficient linguistic skills until around three years of age. Results: This study included 639 patients; 412 (64%) patients aged under three years and 227 (36%) patients aged three years and older. We identified 241 ADEs in 639 patients; 152 ADEs among patients aged under three years (37 ADEs per 100 patients) and 89 ADEs among those aged three years and older (39 ADEs per 100 patients). ADEs among patients aged under three years were less likely to be found (49 ADEs) during their hospital stay than those aged three years and older (20 ADEs) ( P = 0.02). Among 172 MEs identified in 639 patients, 25 MEs (15%) resulted in ADEs; 23 (92%) occurred to those aged under three years and two (8%) occurred to those aged three years and older ( P = 0.0008). Conclusion: ADEs were less likely to be found and MEs resulted in ADEs more frequently in patients under three years old, and these differences could be explained by differences in their linguistic skill levels.
- Open Access
- 1 January 2020
- Published by FapUNIFESP (SciELO) in Journal of Inborn Errors of Metabolism and Screening
- Vol. 8
Obituary: Toshiyuki Fukao (1961-2020), a friend of the Latin American IEM community
It is very sad to inform you that Professor Toshiyuki Fukao (Toshi) passed away at the age of 58. Since he was too young and he deceased suddenly, I cannot believe that he is not here.
- 1 January 2020
- Published by FapUNIFESP (SciELO) in Journal of Inborn Errors of Metabolism and Screening
- Vol. 8
Open AccessObituary: Toshiyuki Fukao (1961-2020), a friend of the Latin American IEM community
It is very sad to inform you that Professor Toshiyuki Fukao (Toshi) passed away at the age of 58. Since he was too young and he deceased suddenly, I cannot believe that he is not here.
- 14 March 2019
- Published by Springer Nature
- p. 57-65
Gaucher Disease
- 1 March 2019
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 126 (3) , 238-245
Critical review of current MPS guidelines and management
- 1 March 2019
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 126 (3) , 238-245
Critical review of current MPS guidelines and management
- Open Access
- 1 July 2016
- Published by Elsevier in Blood Cells, Molecules, and Diseases
- Vol. 59, 37-43
Development of anti-velaglucerase alfa antibodies in clinical trial-treated patients with Gaucher disease
- 1 July 2016
- Published by Elsevier in Blood Cells, Molecules, and Diseases
- Vol. 59, 37-43
Open AccessDevelopment of anti-velaglucerase alfa antibodies in clinical trial-treated patients with Gaucher disease
- Open Access
- 1 July 2016
- Published by Elsevier in Blood Cells, Molecules, and Diseases
- Vol. 59, 140-147
A multicenter, open-label extension study of velaglucerase alfa in Japanese patients with Gaucher disease: Results after a cumulative treatment period of 24 months
- 1 July 2016
- Published by Elsevier in Blood Cells, Molecules, and Diseases
- Vol. 59, 140-147
Open AccessA multicenter, open-label extension study of velaglucerase alfa in Japanese patients with Gaucher disease: Results after a cumulative treatment period of 24 months